Literature DB >> 10542110

Simultaneous assay of Src SH3 and SH2 domain binding using different wavelength fluorescence polarization probes.

B A Lynch1, C Minor, K A Loiacono, M R van Schravendijk, M K Ram, R Sundaramoorthi, S E Adams, T Phillips, D Holt, R J Rickles, I A MacNeil.   

Abstract

pp60(c-src) is a prototypical nonreceptor tyrosine kinase and may play a role in diseases as diverse as cancer and osteoporosis. In Src, the SH3 domain (Src homology 3) binds proteins at specific, proline-rich sequences, while the SH2 domain (Src homology 2) binds phosphotyrosine-containing sequences. Inhibition of Src SH3 and SH2 domain function is of potential therapeutic value because of their importance in signaling pathways involved in disease states. We have developed dual-wavelength fluorescent peptide probes for both the Src SH3 and the Src SH2 domains, which allow the simultaneous measurement of compounds binding to each domain in assays based on the technique of fluorescence polarization. We demonstrate the utility of these probes in a dual-binding assay (suitable for high-throughput screening) to study the interactions of various peptides with these domains, including a sequence from the rat protein p130(CAS) which has been reported to bind simultaneously to both Src SH3 and SH2 domains. Utilizing this dual-binding assay, we confirm that sequences from p130(CAS) can simultaneously bind Src via both its SH3 and its SH2 domains. We also use the dual-binding assay as an internal control to identify substances which inhibit SH3 and SH2 binding via nonspecific mechanisms. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10542110     DOI: 10.1006/abio.1999.4305

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  2 in total

1.  Binding Characterization of Cyclic Peptide Ligands to Target Proteins and Chemical Epitopes Using ELISA and Fluorescence Polarization Assays.

Authors:  Ariane Borges; Iryna Onasenko; Arundhati Nag
Journal:  Methods Mol Biol       Date:  2022

2.  Identification and rational redesign of peptide ligands to CRIP1, a novel biomarker for cancers.

Authors:  Jihua Hao; Adrian W R Serohijos; Gail Newton; Gina Tassone; Zuncai Wang; Dennis C Sgroi; Nikolay V Dokholyan; James P Basilion
Journal:  PLoS Comput Biol       Date:  2008-08-01       Impact factor: 4.475

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.